NASDAQ:FIXX

Homology Medicines Stock Forecast, Price & News

$6.36

-0.14 (-2.15 %)

(As of 07/30/2021 12:00 AM ET)

Add

Compare

Today's Range

$6.33

▼

$6.57

50-Day Range

$6.02

▼

$7.45

52-Week Range

$5.94

▼

$15.24

Volume257,497 shs

Average Volume436,203 shs

Market Capitalization$363.03 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.4

30 days | 90 days | 365 days | Advanced Chart

Receive FIXX News and Ratings via Email

Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter.

About Homology Medicines

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II. Homology Medicines, Inc. was incorporated in 2015 and is based in Bedford, Massachusetts.

Stock Traders Buy Large Volume of Call Options on Homology Medicines (NASDAQ:FIXX)
July 29, 2021 | americanbankingnews.com

$630,000.00 in Sales Expected for Homology Medicines, Inc. (NASDAQ:FIXX) This Quarter
July 18, 2021 | americanbankingnews.com

Brokerages Expect Homology Medicines, Inc. (NASDAQ:FIXX) to Announce -$0.58 EPS
July 16, 2021 | americanbankingnews.com

Homology Medicines, Inc. Common Stock (FIXX)
July 14, 2021 | nasdaq.com

Homology Medicines (NASDAQ:FIXX) Rating Reiterated by Chardan Capital
July 10, 2021 | americanbankingnews.com

Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 21%
May 22, 2021 | nasdaq.com

Homology Medicines Inc (FIXX-Q) Quote - Press Release - The Globe and Mail
May 14, 2021 | theglobeandmail.com

Homology Medicines Announces Presentations on its Expanding Genetic Medicines Platform and Internal GMP Manufacturing at the American Society of Gene & Cell Therapy Annual Meeting
May 13, 2021 | finance.yahoo.com

Homology Medicines Reports First Quarter 2021 Financial Results and Recent Highlights
May 6, 2021 | finance.yahoo.com

Homology Medicines (FIXX) Reports Q1 Loss, Tops Revenue Estimates
May 6, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FIXX
Previous Symbol
CUSIPN/A
CIK1661998
Webwww.homologymedicines.com
Phone781-301-7277
Employees205
Year FoundedN/A

Sales & Book Value

Annual Sales$2.70 million
Price / Sales134.46
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.33 per share
Price / Book1.47

Profitability

EPS (Most Recent Fiscal Year)($2.80)
Net Income$-128,690,000.00
Net Margins-300.57%
Return on Equity-49.59%
Return on Assets-38.35%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares57,080,000
Market Cap$363.03 million
Next Earnings Date8/9/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

2.05 out of 5 stars

Medical Sector

486th out of 2,223 stocks

Pharmaceutical Preparations Industry

244th out of 869 stocks

3.4 Analyst's Opinion

Consensus Rating
Homology Medicines has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.20, Homology Medicines has a forecasted upside of 280.5% from its current price of $6.36.
Amount of Analyst Coverage
Homology Medicines has only been the subject of 2 research reports in the past 90 days.

4.4 Community Rank

Outperform Votes
Homology Medicines has received 105 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Homology Medicines has received 52 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Homology Medicines has received 66.88% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Homology Medicines and other stocks. Vote “Outperform” if you believe FIXX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FIXX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Homology Medicines does not currently pay a dividend.
Dividend Growth
Homology Medicines does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Homology Medicines insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.70% of the stock of Homology Medicines is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
50.32% of the stock of Homology Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Homology Medicines are expected to decrease in the coming year, from ($1.86) to ($2.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Homology Medicines is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Homology Medicines is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Homology Medicines has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions

Is Homology Medicines a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Homology Medicines stock.
View analyst ratings for Homology Medicines or view top-rated stocks.

What stocks does MarketBeat like better than Homology Medicines?

Wall Street analysts have given Homology Medicines a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Homology Medicines wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Homology Medicines' next earnings date?

Homology Medicines is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Homology Medicines.

How were Homology Medicines' earnings last quarter?

Homology Medicines, Inc. (NASDAQ:FIXX) issued its quarterly earnings data on Thursday, May, 6th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.59. The business had revenue of $29.31 million for the quarter, compared to analysts' expectations of $0.78 million. Homology Medicines had a negative trailing twelve-month return on equity of 49.59% and a negative net margin of 300.57%.
View Homology Medicines' earnings history.

How has Homology Medicines' stock price been impacted by COVID-19 (Coronavirus)?

Homology Medicines' stock was trading at $17.91 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FIXX shares have decreased by 64.5% and is now trading at $6.36.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for FIXX?

4 brokerages have issued 1-year target prices for Homology Medicines' stock. Their forecasts range from $14.00 to $34.00. On average, they expect Homology Medicines' share price to reach $24.20 in the next twelve months. This suggests a possible upside of 280.5% from the stock's current price.
View analysts' price targets for Homology Medicines or view top-rated stocks among Wall Street analysts.

Who are Homology Medicines' key executives?

Homology Medicines' management team includes the following people:

Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 58, Pay $885.96k)
Mr. W. Bradford Smith, CFO & Treasurer (Age 65, Pay $582.38k)
Dr. Albert Seymour Ph.D., Chief Scientific Officer (Age 53, Pay $607.58k)
Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory Board
Mr. Timothy P. Kelly, Chief Operating Officer (Age 52)
Dr. Paul Alloway J.D., Ph.D., Sr. VP & Gen. Counsel
Ms. Theresa McNeely, Chief Communications Officer & Patient Advocate (Age 57)
Ms. Melissa Gelormini, VP of HR
Dr. Gabriel M. Cohn M.B.A., M.D., Chief Medical Officer (Age 62)
Mr. Michael Blum M.B.A., Sr. VP of Commercial

Who are some of Homology Medicines' key competitors?

Some companies that are related to Homology Medicines include Amneal Pharmaceuticals (AMRX), Zymeworks (ZYME), ADC Therapeutics (ADCT), Y-mAbs Therapeutics (YMAB), COMPASS Pathways (CMPS), Madrigal Pharmaceuticals (MDGL), Innoviva (INVA), Day One Biopharmaceuticals (DAWN), Supernus Pharmaceuticals (SUPN), Nurix Therapeutics (NRIX), PureTech Health (PRTC), uniQure (QURE), Zealand Pharma A/S (ZEAL), Kura Oncology (KURA) and Heron Therapeutics (HRTX).
View all of FIXX's competitors.

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), (CGC) and Inovio Pharmaceuticals (INO).

When did Homology Medicines IPO?

(FIXX) raised $100 million in an IPO on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI served as the underwriters for the IPO and BTIG was co-manager.

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by a variety of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (0.10%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Timothy P Kelly and W Bradford Smith.
View institutional ownership trends for Homology Medicines.

Which institutional investors are buying Homology Medicines stock?

FIXX stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P..
View insider buying and selling activity for Homology Medicines or or view top insider-buying stocks.

How do I buy shares of Homology Medicines?

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $6.36.

How much money does Homology Medicines make?

Homology Medicines has a market capitalization of $363.03 million and generates $2.70 million in revenue each year. The company earns $-128,690,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.

How many employees does Homology Medicines have?

Homology Medicines employs 205 workers across the globe.

What is Homology Medicines' official website?

The official website for Homology Medicines is www.homologymedicines.com.

Where are Homology Medicines' headquarters?

Homology Medicines is headquartered at ONE PATRIOTS PARK, BEDFORD MA, 01730.

How can I contact Homology Medicines?

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.

This page was last updated on 7/31/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here